We report the use of axonal transport to achieve intraneural drug delivery. We constructed a novel tripartite complex of an axonal transport facilitator conjugated to a linker molecule bearing up to a hundred reversibly attached drug molecules. The complex efficiently enters nerve terminals after intramuscular or intradermal administration and travels within axonal processes to neuron cell bodies. The tripartite agent provided 100-fold amplification of saturable neural uptake events, delivering multiple drug molecules per complex. In vivo, analgesic drug delivery to systemic and to non-targeted neural tissues was greatly reduced compared to existing routes of administration, thus exemplifying the possibility of specific nerve root targeting and effectively increasing the potency of the candidate drug gabapentin 300-fold relative to oral administration.
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We report the use of axonal transport to achieve intraneural drug delivery. We constructed a novel tripartite complex of an axonal transport facilitator conjugated to a linker molecule bearing up to a hundred reversibly attached drug molecules. The complex efficiently enters nerve terminals after intramuscular or intradermal administration and travels within axonal processes to neuron cell bodies. The tripartite agent provided 100-fold amplification of saturable neural uptake events, delivering multiple drug molecules per complex. In vivo, analgesic drug delivery to systemic and to non-targeted neural tissues was greatly reduced compared to existing routes of administration, thus exemplifying the possibility of specific nerve root targeting and effectively increasing the potency of the candidate drug gabapentin 300-fold relative to oral administration.
INTRODUCTION
Pharmacological entrainment of axonal transport for the purpose of targeted drug deliver to selected sites is acknowledged as a highly desirable objective since it would allow for targeted antiviral, antineuropathic or regenerative treatments to segmentally selected ganglion or CNS cells. Methods using direct injection into nerves 1 , introduction of modified neurotropic viruses 2 , or delivery of neurotoxins such as tetanus toxin or ricin 3, 4 have been explored but each pose barriers to routine clinical use. Phage display has been used to generate synthetic peptides to promote axonal transport 5 , but it has not been clear how to exploit this.
Retrograde axonal transport of exogenous molecules from the periphery to CNS neuronal cell bodies is long established 6 and is one of the methodological bases for mapping neuroanatomical pathways [7] [8] [9] . The underlying physiology and biochemistry are increasingly well understood [10] [11] [12] [13] [14] . However, although axonal transport for drug delivery has been proposed previously [15] [16] [17] [18] [19] , little or nothing is known about the major features of this biological system from the point of view of approaching it pharmacologically and there has been no agent demonstrated capable of accomplishing a clinical effect via this route.
We designed a novel type of molecular complex to achieve this. The agents used are various forms of a tripartite complex composed of a first moiety acting as an "axonal transport facilitator" (ATF), an "amplifying polymer" (AP) second moiety acting to achieve amplification of the fundamental event of synaptic endocytosis by carrying along
multiple drug molecules with each saturable uptake event, and a third moiety composed of multiple copies of the therapeutic molecule, reversibly linked to the polymer (Fig. 1 ).
We were able to administer a small intramuscular injection with 1/300 th of the usual oral dose of gabapentin (half life 8 hours) and achieve a degree of neuropathic pain suppression that could not be obtained with tolerable amounts of oral therapy while extending the half life of the drug by more than an order of magnitude.
MATERIALS AND METHODS
These are summarized in II -Intracellular release and drug activation [3] .
The stability of a drug is maintained through chemical linkage and biological release
In the BHK viral plaque reduction experiments, free drug in the culture medium resulted in plaque reduction by 96% at a dose of 5 micrograms/well, but a dose of 50 micrograms/well of the drug bound to dextran was required to achieve an equivalent effect. However we observed nearly 100% plaque reduction using a dose of 5 microgram/well of tripartite WGA-dextran-drug conjugate. This demonstrates that the [4] . Effects of polymer size on tripartite uptake into nerves 10,000 MW dextran achieved more avid and rapid axonal uptake than 70,000 MW dextran. Dextran 70K based material is taken up effectively but at a lower rate. With 10K dextran, there is extensive uptake within ten minutes after application and washing.
Similar levels of uptake are seen with 70K dextran after 60 minutes. However the differential efficacy of uptake was not large enough to outweigh the benefits of greater amplification of uptake events achieved by using the higher capacity larger molecules for drug delivery. Since molecular loading of the polymers was equivalent for various sized dextrans, the increased drug delivery with increased molecular size was linear. However,
the losses in uptake efficiency with larger molecules appeared to be much less than linear. The consequence is that although smaller dextran molecules were endocytosed more avidly and rapidly than 70K based vehicles, more drug molecules were still delivered by the 70K based vehicles.
[5]. Effects of charge on uptake and transport
The overall charge of the complex had a large impact on efficiency of uptake ( Fig. S-5 ). There was virtually no uptake into cultured neurons when the overall charge of the complex was negative, and effective uptake occurred when charge was neutral, or when overall charge was positive.
[6]. Effects of side group mediated hydrophobicity on uptake and transport Acylation of FITC-labeled, WGA-conjugated dextran to make the molecules progressively hydrophobic led to complete failure of uptake and transport. We assessed various degrees of acylation and found that this effect occurred even at very low ratios of acylation.
IV -Effects of axonal transport facilitator [7] , [8] , [9] . Efficacy of physiologic, non-physiologic and synthetic ATFs
The Campenot chamber studies demonstrated similar efficacy for Nerve growth factor (NGF) and WGA for producing uptake of the tripartite carrying FITC (Fig. S-6 ).
The phage display experiments demonstrated that novel purely synthetic ATFs could be discovered and then produced in vitro which not only had equivalent efficiency for neuronal uptake, but which could also be more efficiently sub-targeted to different types of neuronal populations (e.g. general sensory, pain, motor, autonomic). Blockage of movement of compounds with phage derived synthetic ATF by the use of axonal transport inhibitors confirmed that purely synthetic ATFs had been generated, identified, and produced.
V. Effects of intra-axonal processing [10] .
Survival of small chemical molecules linked to the tripartite
When WGA-dextran-gabapentin was used, cross staining with antibodies to gabapentin confirmed preserved antigenicity of the drug after axonal transport of the tripartite, although this method could not itself confirm that the drug was intact or active after transport and release. Dextran-gabapentin with no conjugated WGA did not produce detectable gabapentin antigenicity in the histological sections. reports concerning WGA 20 and NGF 21 and their intramuscular introduction 22 23 .
The rate of transport appeared to be consistent with time scales predicted by literature values of 30-100 mm/day 24 . Overall the area of spread of injectate was limited to a few millimeters, although the distribution in the epaxial muscle spinal cord motorneuron pool extended over several centimeters.
[12], [13] , [14] , [15] .
Intact transport of targeted nanoparticles by intact axon termini
Electron microscopy showed appropriately sized ferrites within the axon, more than three centimeters from the WGA-dextran-Fe injection site (Fig. 4) . The appearance 25 , but in this case the particles were restricted to the axonal stream. The autoradiographic studies demonstrated sciatic nerve radioactivity and so provided similar evidence that the magnetite containing particles were transported in nerves.
The relaxivity experiments ( The WGA-dextran-magnetite experiments in rabbits confirm other reports 26 that particles of 5-15nm are endocytosed and transported by intact nerve endings. Some studies have suggested that nerve injury is required for the transport of larger particles 27 , but this result suggests that intact neurons will indeed transport large (up to 15nm) multimolecular aggregates or "transport particles" after intramuscular injection when the particles are well solvated. [16] , [17] , [18] , [19] . Targeted Access to Clinically Relevant Neuronal Subpopulations Intramuscular injection of the tripartite WGA-dextran-FITC produced labeling of alpha motor neurons in the ventral horn and autonomic neurons in the intermediolateral cell column (Fig. 2d, 2e ). We also observed good filling of proximal sensory neuron processes (axons) in the dorsal root entry zone and in lamina I and II of the dorsal horn of the spinal cord ( Fig. S-9 ). Injection of foot pad and multiple hind limb muscle each resulted in labeling of less than 50% of ganglion cells, but injection of both muscle and skin resulted in filling of nearly 90% of dorsal root ganglion (DRG) cells (Fig. 2f, 2g , S-10). In clinical use, the objective will typically be to reach specific sub-populations rather than filling an entire ganglion per se, so these results support the expectation that a large fraction of cells in a e.g. a subpopulation innervating a single muscle or patch of skin can readily be reached.
Cross staining with an antibody to peripherin showed that many of the DRG sensory neurons that were accessed were C-fiber nociceptor cells (Fig. 3a to 3f ). This helps confirm that this method of delivery does reach a selected subset of nociceptors that correlates specifically with the selected site of injection. The ATF played a major role since no detectable fluorescence was observed when dextran-FITC without ATF was administered in these experiments. (Fig. S-11 ) and demonstrated saturability and transport time consistent with other reports 28 .
Activity in spinal cord was less than in nerve or DRG but did reach twice systemic concentrations when higher concentrations of injectate were used. The greatest activities detected in other tissues were in liver and kidney and these apparently reflected metabolized iodine. There was no significant activity detected in contralateral nerve and DRGs nor in ipsilateral nerves, ganglia, or spinal cord related to cervical, thoracic, or higher lumbar segments. NGF showed less transport to spinal cord than was seen for WGA consistent with selective uptake of NGF by sensory and autonomic nerves.
Detection of activity due to [ 59 Fe]-WGA-dextran-at other systemic sites was even less than for WGA or NGF alone.
Considerable amounts of drug remained in the axon itself at the time points sampled. It is known that para-nodal complexes of Schwann cells at the Nodes of Ranvier can endocytose materials from the axoplasm 29 and this may account for a peri-axonal depot effect with drug being cleared to the para-nodal complexes and then subsequently being re-released. Further studies will be needed to clarify this issue.
[21]. Site of injection retains high amount of injectate
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The regional view provided by the [ 131 I]-WGA gamma camera studies demonstrates that the total amount of the injectate remaining at the site of injection is large when compared to the amount in the small volume of the nerve. In part, this reflects the fact that WGA adheres to muscle cell membranes 30 as well as being taken up by adsorptive endocytosis at nerve termini. This also explains a depot effect whereby additional amounts of the compound continue to be introduced into the axonal stream over a period of several days.
[22]. Pharmacologically efficacious drug amounts were delivered
The tripartite assemblage with [ 14 C]-labeled gabapentin produced activity levels for gabapentin in ipsilateral neurons of more than 600 times greater than background while counts remained at background levels in contralateral neurons. This demonstrated the localizing effect of injection of polymer-bound drug conjugated to an axonal transport facilitator, and also allowed us to estimate the drug concentration achieved based on the specific activity of the [ 14 C]-labeled gabapentin.
VIII -The pharmacologic effects of ATF mediated delivery are not obtainable by trans-vascular agents [23] .
Prolonged suppression of hyperalgesia
In the hyperalgesia experiments a single injection with the tripartite agent reduced the hyperalgesia (p<0.05 in eight out of the nine comparisons of treatment versus control) for at least four days after injection ( suggested delivery of gabapentin at intracellular doses equal to or greater than 100 M.
These in vivo [ 14 C]-gabapentin studies therefore showed that this technology can deliver drugs to target neurons at pharmacologically efficacious doses using 1/300 th of the oral dose that would be required to achieve the same intracellular concentration in target cells.
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In addition, this system resulted in a ten fold increase in effective half life relative to oral administration. This appears to be because of the unique dynamics of this delivery mechanism. This involves both a muscle injection site depot effect for the large tripartite complexes and a prolonged stream of delivery to the neuron from the axon and its associated paranodal complexes.
In this set of experiments, neither systemic delivery of the agent by a subcutaneous route nor administration of free drug alone to the affected limb had any significant therapeutic effect. Although dextran can itself weakly promote axonal transport 33 , the use of dextran/drug with no ATF showed only limited effect in occasional animals and was in no case statistically significant. Amplification by an additional order of magnitude through alternative conjugation schemes appears to be readily achievable.
We anticipate that intraneural pain medication will have a significant impact on the management of pain after surgery and in the treatment of patients suffering from 
